It is assumed that 8--16% of all epithelial ovarian cancer (EOC) cases are due to *BRCA1/2* germ line mutations ([@bib5]; [@bib6]; [@bib1]). An improved survival after primary therapy has been reported for *BRCA1/2*-associated compared with sporadic EOC patients ([@bib7]; [@bib9]; [@bib3]). This is thought to be explained by the crucial role of *BRCA* genes in homologous recombination, a mechanism to repair double-strand DNA breaks, which is deficient in patients without functional BRCA proteins. Platinum chemotherapy, like cisplatin or carboplatin, being a cornerstone in EOC treatment, typically induces double-strand DNA breaks leading to more cancer cell death in *BRCA1/2* mutation carriers.

Around 30--50% of the *BRCA1/2*-associated EOC patients have been treated for previous breast cancer (BC; [@bib1]; [@bib8]), whereas data on the incidence of EOC after BC in *BRCA1/2* mutation carriers are scarce. Metcalfe reported a 10-year actuarial risk of developing EOC after BC of 12.7% for *BRCA1* and of 6.8% for *BRCA2* mutation carriers (*P*=0.03) ([@bib4]). Currently it is unknown whether a BC history affects the outcome of subsequent EOC in *BRCA1/2* mutation carriers, especially as treatment for early *BRCA-*associated BC frequently includes adjuvant chemotherapy.

In the current study we evaluated the outcome of EOC in *BRCA1/2* mutation carriers with and without a BC history. In addition, we investigated the impact of adjuvant chemotherapy for BC on the outcome of *BRCA1/2*-associated EOC.

Materials and methods
=====================

Patients
--------

Initially, we selected EOC patients identified with a *BRCA1* or *BRCA2* mutation, diagnosed between 1980 and 2008 from databases at all eight Dutch University Medical Centres, one Cancer Centre and the Netherlands Foundation for the Detection of Hereditary Tumours (STOET), as has been described previously ([@bib8]). In four centres both *BRCA1* and *BRCA2* patients were included, whereas in six centres, due to a lower prevalence, only *BRCA2* patients were included. In addition, from the Erasmus MC in Rotterdam *BRCA1/2*-associated EOC patients treated between 2008 and 2015 were included. Exclusion criteria were a previous malignancy (except for BC and basal cell carcinoma), a borderline ovarian tumour and a primary or recurrent BC synchronous with EOC.

For the selected patients, data concerning tumour characteristics, treatment for BC and EOC, and follow-up were collected from medical records. The medical ethical committee of the Erasmus MC, Rotterdam (MEC-2014--429) approved the study.

Definitions
-----------

The main outcome measures were progression-free survival (PFS), progression-free interval (PFI), overall survival (OS) and ovarian cancer-specific survival (OCSS).

Progression-free survival was defined as the time between the date of EOC diagnosis and the date of progressive or recurrent disease. Progression-free interval was defined as the time between the last day of first-line treatment for EOC and the date of progressive/recurrent disease. The end date of chemotherapy was estimated if the last day of chemotherapy was unknown. Overall survival was defined as the time between date of EOC diagnosis and date of death. Ovarian cancer-specific survival was defined as the time between the date of EOC diagnosis and the date of death due to EOC.

Statistics
----------

Differences in tumour and treatment characteristics between EOC patients with and without a history of BC were tested with the Pearson\'s *χ*^2^-test or, in case of small numbers, with the Fisher\'s exact test (categorical variables) or with the Student\'s *t*-test (continuous variables). Progression-free survival, PFI, OS and OCSS were calculated using the Kaplan--Meier survival method for patients with and without a previous BC separately. Subsequent analyses were performed for the group of patients treated with and without adjuvant chemotherapy for a previous BC separately. To account for the time elapsed between EOC diagnosis and genetic testing, we performed left-truncated survival analyses. Patients were censored at date of loss to follow-up, or end date of the study (April 2015). For PFS, PFI and OCSS patients were also censored at date of death not due to EOC. Differences between the groups were tested by means of a log rank test. Univariate as well as multivariate Cox proportional hazard regression models were performed, to calculate hazard ratio\'s (HRs) and 95% confidence intervals (95% CIs). Following confounding factors were included in the multivariate regression model: age at EOC diagnosis (continuous), year of EOC diagnosis (\<2000; ⩾2000), CA-125 level at diagnosis (\<35; 35--500; \>500; unknown), differentiation grade (grade I and grade II; grade III; unknown), FIGO stage (I- IIa;\>IIa; unknown), type of mutation (*BRCA1*; *BRCA2*) and chemotherapy regimen for EOC (platinum/paclitaxel; platinum without paclitaxel; non-platinum-based; unknown). Analyses were performed using SPSS (version 21.0; SPSS, Inc., Chicago, IL, USA) or Stata (version 14; Stat Corporation, College Station, TX, USA). A two-sided *P*-value\< 0.05 was considered statistically significant.

Results
=======

Patient, tumour and treatment characteristics of 116 EOC patients with previous BC and 270 without previous BC are presented in [Table 1](#tbl1){ref-type="table"}. In [Supplementary Table 1](#sup1){ref-type="supplementary-material"}, data on BC treatment are summarised. The median age at EOC diagnosis was 51.8 for *BRCA1* and 56.3 years for *BRCA2* patients, and 73% of the patients were diagnosed with advanced stage disease (⩾ FIGO stage IIb). CA-125 values at EOC diagnosis were lower in the group with previous BC (*P*=0.02). The patients with previous BC were less often tested for *BRCA1/2* mutations after their EOC diagnosis (*P*\<0.001). There were no other significant differences between the characteristics of the two patient groups, with and without previous BC, observed ([Table 1](#tbl1){ref-type="table"}).

Progression-free survival was not significantly different for patients with previous BC compared with patients without a previous BC (5-year PFS 22% *vs* 28% [Figure 1a](#fig1){ref-type="fig"} and [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). In the multivariate analysis, however, PFS was significantly lower in the group with previous BC (HR multivariate (HR~mult)~ 1.47; 95% CI 1.03--2.08). Similar data were observed for PFI, at univariate analysis no significant difference was found between the two patient groups, whereas in the multivariate analysis the group with a history of BC had a shorter PFI (HR~mult~ 1.43; 95% CI 1.01--2.03; [Figure 1b](#fig1){ref-type="fig"} and [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). No significant difference was found regarding OS (HR~mult~ 1.15; 95% CI 0.84--1.57) and OCSS (HR~mult~ 1.18; 95% CI 0.85--1.62) between patients with and without a history of BC ([Supplementary Table 2](#sup1){ref-type="supplementary-material"} and [Figure 1c and d](#fig1){ref-type="fig"}). The time between BC diagnosis and EOC diagnosis was not associated with PFS (HR~mult~ 1.00; 95% CI 0.96--1.04), nor with OCSS (HR~mult~ 0.99; 95% CI 0.95--1.04; data not shown).

To address the possible impact of adjuvant chemotherapy administered for BC on the PFS and OCSS of subsequent EOC patients with BC before OC treated with chemotherapy and patients not treated with adjuvant chemotherapy for BC were separately analysed and compared with EOC patients without previous BC ([Figure 2](#fig2){ref-type="fig"} and [Supplementary Table 3](#sup1){ref-type="supplementary-material"}). We observed that PFS and OCSS were especially worse for patients treated with adjuvant chemotherapy for previous BC *vs* patients without previous BC (median 1.5 *vs* 2.0, and median 5.0 *vs* 5.3 years, respectively). In the multivariate analyses these differences were significant (HR~mult~ 2.38; 95% CI 1.40--4.02 and HR~mult~ 1.99; 95% CI 1.21--3.31, respectively). The patients with a BC history not treated with adjuvant chemotherapy had similar PFS and OCSS compared with EOC patients without a BC history (HR~mult~ 1.16; 95% CI 0.76--1.79 and HR~mult~ 0.87; 95% CI 0.59--1.29, respectively; [Figure 2](#fig2){ref-type="fig"} and [Supplementary Table 3](#sup1){ref-type="supplementary-material"}).

Discussion
==========

In the current study, we observed a significantly worse PFS and PFI, in *BRCA*-associated EOC patients with a BC history *vs* EOC patients without a previous BC, not yet resulting in a significantly worse survival. A significantly worse OCSS, however, was found in *BRCA*-associated EOC patients treated with adjuvant chemotherapy for BC compared with EOC patients without previous BC.

No differences in grade, stage and histology were observed between both groups. A first hypothetical explanation for this survival difference might be that chemotherapy induces mutations and alters the behaviour of already present malignant EOC cells, or induces chromosomal instability in stem cells with subsequent development of EOC. Another possible explanation might be that treatment for the initial BC aggravates the (bone marrow) condition of the patient and, therefore, optimal therapy for EOC cannot be given to these patients. However, the time between BC diagnosis and OC diagnosis was not associated with outcome, suggesting that the condition of the patients is not the main reason for the worse survival in patients with a BC history.

The retrospective nature of the study brings corresponding limitations, such as different treatments regimens, and some missing data. Another limitation includes that the majority of the patients were tested for a *BRCA1/2* mutation after EOC diagnosis (64% and 82% in the groups with and without a BC history, respectively), this will select for survivors. To account for this possible survivorship bias we have conducted left-truncation survival analyses. Because of the retrospective design, no firm conclusions can be drawn and our results should be confirmed in other (prospective) studies with greater sample size.

The results of this study underline the importance of offering genetic testing to BC patients being at risk of *BRCA1/2* mutation carriership. Newly diagnosed mutation carriers can then be informed about risk reducing salpingo-oophorectomy, which has been associated with improved survival ([@bib2]). Further, we suggest that studies on survival in *BRCA1/2*-associated EOC should stratify for BC history.
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![Progression free survival (**A**), progression free interval (**B**), overall survival (**C**) and ovarian cancer-specific survival (**D**) for *BRCA1/2* epithelial ovarian cancer patients with and without a BC history. BC, breast cancer; CI, confidence interval; HR, hazard ratio.](bjc2016333f1){#fig1}

![Progression free survival (**A**) and ovarian cancer-specific survival (**B**) for *BRCA1/2* epithelial ovarian cancer patients with and without adjuvant chemotherapy for BC and without a BC history. BC, breast cancer; CT, chemotherapy.](bjc2016333f2){#fig2}

###### Patient, tumour and treatment characteristics of OC in *BRCA1/2* patients with and without a history of BC

                                                                      **Patients with a history of BC** ***N***   **%**   **Patients without a history of BC** ***N***   **%**   ***P*****-value**
  ------------------------------------------------------------------ ------------------------------------------- ------- ---------------------------------------------- ------- -------------------
  Total number of patients                                                               116                       30                         270                         70              
  Age at diagnosis                                                                                                                                                                     0.09
   Median in years (range)                                                        53.1 (39.0--77.1)                                    52.0 (23.2--89.7)                                  
   Mean in years (s.d.)                                                              54.3 (8.3)                                            52.6 (9.1)                                     
  Follow-up time                                                                                                                                                                       0.15
   Median in years (range)                                                         4.9 (0.4--33.4)                                      5.6 (0.1--33.1)                                   
  Type of mutation                                                                                                                                                                     0.18
   *BRCA1*                                                                               89                        77                         188                         70              
   *BRCA2*                                                                               27                        23                          82                         30              
  *BRCA1/2* testing after EOC diagnosis[a](#t1-fn2){ref-type="fn"}                       71                        64                         211                         82          \<0.001
   Mean time after EOC in years                                                          3.6                                                  4.3                                      0.28
   Median time after EOC in years                                                        1.4                                                  2.2                                         
  Year of diagnosis                                                                                                                                                                    0.16
   1980--1989                                                                             9                         8                          32                         12              
   1990--1999                                                                            35                        30                          83                         31              
   2000--2009                                                                            60                        52                         142                         53              
   ⩾2010                                                                                 12                        10                          13                          5              
  CA-125 (kU l^-1^) at primary diagnosis                                                                                                                                               0.02
   \<35                                                                                  19                        16                          20                          7              
   35--500                                                                               28                        24                          81                         30              
   \>500                                                                                 31                        27                          94                         35              
   Unknown                                                                               38                        33                          75                         28              
  Histology                                                                                                                                                                            0.77
   Serous                                                                                75                        65                         166                         62              
   Mucinous                                                                               5                         4                          8                           3              
   Endometrioid                                                                           8                         7                          28                         10              
   Clear cell                                                                             0                         0                          3                           1              
   Undifferentiated                                                                       7                         6                          18                          7              
   Adenocarcinoma NOS                                                                    16                        14                          34                         13              
   Other                                                                                  1                         1                          6                           2              
   Unknown                                                                                4                         3                          7                           3              
  Tumour grade (Silverberg)                                                                                                                                                            0.99
   1 (well differentiated)                                                                5                         4                          11                          4              
   2 (moderately differentiated)                                                         24                        21                          55                         20              
   3 (poorly differentiated)                                                             72                        62                         172                         64              
   Unknown                                                                               15                        13                          32                         12              
  FIGO stage                                                                                                                                                                           0.56
   I                                                                                     17                        15                          29                         11              
   II                                                                                    15                        13                          35                         13              
   III                                                                                   57                        49                         153                         57              
   IV                                                                                    23                        20                          48                         18              
   Unknown                                                                                4                         3                          5                           2              
  Surgery                                                                                                                                                                              0.71
   Primary surgery                                                                       81                        70                         172                         64              
   Interval debulking                                                                     9                         8                          24                          9              
   Both                                                                                  24                        21                          70                         26              
   None                                                                                   0                         0                          1                           0              
   Unknown                                                                                2                         2                          3                           1              
  Radiotherapy                                                                                                                                                                         0.79
   Yes                                                                                    5                         4                          10                          4              
   No                                                                                    103                       89                         236                         87              
   Unknown                                                                                8                         7                          24                          9              
  Chemotherapy                                                                                                                                                                         0.68
   Platinum with Paclitaxel                                                              77                        66                         182                         67              
   Platinum without Paclitaxel                                                           30                        26                          72                         27              
   Other                                                                                  3                         3                          2                           1              
   No                                                                                     6                         5                          11                          4              
   Unknown                                                                                0                         0                          3                           1              
  Duration of chemotherapy for primary OC                                                                                                                                              0.07
   Median in weeks (range)                                                        18.7 (1.3--47.7)                                      20.0 (2.1--98.6)                                  
   Mean in weeks (s.d.)                                                              20.5 (7.9)                                           22.7 (11.8)                                     

Abbreviations: BC=breast cancer; FIGO=international federation of gynecology and obstetrics; OC=ovarian cancer; NOS=not otherwise specified.

Date of DNA test was missing for 18 patients (5 with and 13 without a BC history).
